We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

55 hedge funds and large institutions have $200M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

30% more capital invested

Capital invested by funds: $154M → $200M (+$46.7M)

0% more funds holding

Funds holding: 5555 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
55
Holders Change
Holders Change %
0%
% of All Funds
1.59%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
25
Reduced
12
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
1
Sectoral Asset Management
Quebec, Canada
$45.3M +$4.3M +127,636 +10%
BI
2
BVF Inc
California
$33.3M -$3.39M -100,700 -9%
CCI
3
Columbus Circle Investors
$23.4M +$11.8M +351,057 +102%
BFA
4
BlackRock Fund Advisors
California
$16.5M +$1.41M +41,923 +9%
Primecap Management
5
Primecap Management
California
$11.5M
Alyeska Investment Group
6
Alyeska Investment Group
Illinois
$8.81M -$600K -17,817 -6%
Franklin Resources
7
Franklin Resources
California
$7.97M
Fidelity Investments
8
Fidelity Investments
Massachusetts
$6.53M
Vanguard Group
9
Vanguard Group
Pennsylvania
$5.07M +$1.53M +45,519 +43%
CCM
10
Cupps Capital Management
Illinois
$4.33M +$4.34M +128,853 New
Bank of America
11
Bank of America
North Carolina
$3.14M +$2.99M +88,682 +1,975%
PAMU
12
Pictet Asset Management (UK)
United Kingdom
$2.73M -$30.3K -900 -1%
BIT
13
BlackRock Institutional Trust
California
$2.56M -$390K -11,567 -13%
VAM
14
Visium Asset Management
New York
$2.52M +$34 +1 +0%
State Street
15
State Street
Massachusetts
$2.43M +$295K +8,766 +14%
Deutsche Bank
16
Deutsche Bank
Germany
$2.28M -$1.67M -49,566 -42%
Northern Trust
17
Northern Trust
Illinois
$1.96M -$195K -5,787 -9%
EAM
18
Eventide Asset Management
Massachusetts
$1.78M +$1.02M +30,300 +135%
Wellington Management Group
19
Wellington Management Group
Massachusetts
$1.68M +$1.69M +50,000 New
Morgan Stanley
20
Morgan Stanley
New York
$1.34M +$943K +27,978 +238%
GPCM
21
Granite Point Capital Management
Massachusetts
$1.21M -$273K -8,100 -18%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.04M +$47.1K +1,399 +5%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.04M +$389K +11,553 +60%
Millennium Management
24
Millennium Management
New York
$968K +$969K +28,760 New
GT
25
Glenmede Trust
Pennsylvania
$965K

OMED Hedge Fund Activity: Q1 2014 in Review

55 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2014, worth a combined $200M — up 30% from $154M a quarter earlier.

Fund positioning in OMED was balanced in Q1 2014: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 12 trimmed.

The largest buyer was Columbus Circle Investors, adding an estimated $11.8M. The largest seller was BVF Inc, cutting an estimated $3.39M.

  • 55 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2014, unchanged from Q4 2013.
  • Funds reported $200M of OncoMed Pharmaceuticals, Inc. stock for Q1 2014, up 30% quarter-over-quarter.
  • 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2014 and 8 closed out, a net change of 0 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2014 was Columbus Circle Investors, an estimated $11.8M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2014 was BVF Inc, an estimated $3.39M sold.

Based on aggregated 13F filings for Q1 2014.